FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Srinivas Devarakonda
- Target Recruit Count
- 1
- Registration Number
- NCT04205240
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CyclosporineBiological: FilgrastimDrug: FludarabineDrug: Mycophenolate MofetilDrug: Mycophenolate SodiumRadiation: Total-Body IrradiationDrug: TreosulfanProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04195633
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
- Conditions
- Interventions
- Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10Drug: FludarabineDrug: CyclophosphamideBiological: Lapine T-Lymphocyte Immune GlobulinRadiation: Total-Body IrradiationProcedure: Hematopoietic Cell TransplantationDrug: Mycophenolate MofetilDrug: SirolimusProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04083183
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Treg Modulation With CD28 and IL-6 Receptor Antagonists
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-10-09
- Target Recruit Count
- 24
- Registration Number
- NCT04066114
- Locations
- 🇺🇸
Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States
🇺🇸University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States
🇺🇸University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States
Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2023-10-17
- Target Recruit Count
- 270
- Registration Number
- NCT04048161
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳First Affiliated Hospital of Zhongshan Medical University, Guangzhou, Guangdong, China
Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil
- Conditions
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT04039373
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04022239
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 823
- Registration Number
- NCT04009525
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT04002115
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
Optimizing PTCy Dose and Timing
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 400
- Registration Number
- NCT03983850
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.